Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
03:06pm, Friday, 27'th Sep 2024
On Thursday, the FDA approved Bristol Myers Squibb & Co's BMY Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
11:45am, Friday, 27'th Sep 2024
Bristol-Myers Squibb's acquisition of Karuna for $14bn and the subsequent FDA approval of Cobenfy, a novel schizophrenia drug, represents a significant strategic win. Cobenfy, the first new schizophre
Pharma Stock Rises on Cleared Schizophrenia Treatment
11:43am, Friday, 27'th Sep 2024
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma name's schizophrenia treatment, Cobenfy.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #PSORIATYK--BMS Presents New Data from Two Trials Demonstrating Sotyktu Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting.
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
11:05am, Friday, 27'th Sep 2024
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
10:18am, Friday, 27'th Sep 2024
Shares of Bristol Myers Squibb (BMY) rose Friday, a day after the Food and Drug Administration (FDA) approved the use of what the pharmaceutical firm called the first treatment for schizophrenia in de
COST Earnings Slip, BMY Schizophrenia Drug Approval, HPQ Downgrade
10:06am, Friday, 27'th Sep 2024
Costco (COST), one of the biggest names in retail, slips after earnings. Despite a beat on the top line and membership fees, revenue and comp.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
10:05am, Friday, 27'th Sep 2024
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers Squibb shares move higher on FDA approval of schizophrenia drug
09:41am, Friday, 27'th Sep 2024
Bristol Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) shares moved higher after the pharmaceutical company's schizophrenia drug was approved by the Food and Drug Administration (FDA), marking the firs
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
07:56am, Friday, 27'th Sep 2024
On Thursday, the FDA approved Bristol Myers Squibb & Co's BMY Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
07:37am, Friday, 27'th Sep 2024
Bristol-Myers Squibb is rated a "Buy" for long-term investors due to the revenue potential of KarXT (Cobenfy) and advancements in its oncology portfolio. Despite recent financial setbacks, BMY's strat
Bristol Myers Stock Jumps. Why Approval for Its Schizophrenia Drug Is Ground Breaking.
06:52am, Friday, 27'th Sep 2024
The drug is one of an emerging class of drugs that has drawn the interest of large pharma companies.
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
05:27am, Friday, 27'th Sep 2024
Bristol Myers Squibb stock (NYSE: BMY) will be in focus in the near term after the U.S. FDA approved Cobenfy for the treatment of Schizophrenia. This is a big approval for the company, given that Cobe
Bristol-Myers Squibb stock jumps on schizophrenia drug approval
04:32am, Friday, 27'th Sep 2024
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia drug.
US drug regulator approves the first new schizophrenia drug in 30 years
03:18am, Friday, 27'th Sep 2024
The US Food and Drug Administration (FDA) has approved Cobenfy, the first new drug for schizophrenia in over 30 years, developed by Bristol Myers Squibb. Taken as a twice-daily pill, the treatment co
